Regorafenib 13CD3 N-Oxide

Regorafenib 13CD3 N-Oxide is a chemical compound that is widely used as a kinase inhibitor in the treatment of various types of cancer. The drug works by inhibiting several protein kinases that play a crucial role in the growth and spread of cancer cells. Regorafenib 13CD3 N-Oxide is a derivative of regorafenib, which is a potent inhibitor of multiple kinases involved in angiogenesis, tumor growth, and metastasis. The chemical formula of Regorafenib 13CD3 N-Oxide is C21H13D3ClF4N4O3, and its molecular weight is 476.84 g/mol. The compound is a stable, white to off-white powder with a melting point of 147°C to 152°C. Regorafenib 13CD3 N-Oxide is soluble in dimethyl sulfoxide and methanol but has limited solubility in water. The recommended dosage of Regorafenib 13CD3 N-Oxide varies depending on the type and stage of cancer being treated. The drug is administered orally, and it is usually taken once a day for 21 days, followed by a 7-day break. The treatment cycle is repeated until the cancer is under control or until the patient experiences adverse effects. Like other cancer drugs, Regorafenib 13CD3 N-Oxide can cause side effects such as fatigue, diarrhea, nausea, vomiting, and loss of appetite. It is important to inform the doctor immediately if any adverse symptoms occur during the treatment. Overall, Regorafenib 13CD3 N-Oxide is a promising drug that has shown significant efficacy in the treatment of various types of cancer, and ongoing research is being conducted to explore its full potential.